Enzon Pharmaceuticals (ENZN) Stock Price, Forecast & Analysis

NASDAQ:ENZN

0.46
+0.01 (+2.22%)
At close: May 19, 2016
0.46
0 (0%)
After Hours: 5/19/2016, 8:47:32 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News

ENZN Key Statistics, Chart & Performance

Key Statistics
Market Cap20.34M
Revenue(TTM)6
Net Income(TTM)N/A
Shares44.22M
Float44.22M
52 Week High1.82
52 Week Low0.39
Yearly Dividend0.15
Dividend Yield38.46%
EPS(TTM)-0.05
PEN/A
Fwd PEN/A
Earnings (Next)N/A
IPON/A
Sector
GICS SectorN/A
GICS IndustryN/A
GICS IndustryGroupN/A
GICS SubIndustryN/A
ENZN short term performance overview.The bars show the price performance of ENZN in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30

ENZN long term performance overview.The bars show the price performance of ENZN in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of ENZN is 0.46 null. In the past month the price decreased by -8%. In the past year, price decreased by -62.3%.

Enzon Pharmaceuticals / ENZN Daily stock chart

ENZN Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating
ENZN Full Technical Analysis Report

ENZN Financial Highlights

Over the last trailing twelve months ENZN reported a non-GAAP Earnings per Share(EPS) of -0.05.


Industry RankSector Rank
PM (TTM) 100.07%
ROA -12.28%
ROE -12.58%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%N/A
Sales Q2Q%N/A
EPS 1Y (TTM)N/A
Revenue 1Y (TTM)N/A
ENZN financials

ENZN Forecast & Estimates


Analysts
AnalystsN/A
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A
ENZN Analyst EstimatesENZN Analyst Ratings

ENZN Ownership

Ownership
Inst Owners0.12%
Ins Owners11.35%
Short Float %0.01%
Short Ratio0.03
ENZN Ownership

About ENZN

Company Profile

Enzon Pharmaceuticals, Inc. is a biotechnology company. It discovers, develops, and commercializes therapeutics to treat life-threatening diseases. The Company's marketed drug products include PegIntron (R) for chronic hepatitis C; Sylatron (R) for Melanoma; Macugen (R) for neovascular age-related macular degeneration; CIMZIA (R) for Crohn's disease; Oncaspar for acute lymphoblastic leukemia; and Adagen for severe combined immunedeficiency. Enzon Pharmaceuticals, Inc. is headquartered in Piscataway, New Jersey.

Company Info

Enzon Pharmaceuticals

20 Commerce Drive Suite 135

Cranford NJ 07016

CEO: Andrew Rackear

Phone: 732-980-4500

Enzon Pharmaceuticals / ENZN FAQ

What does ENZN do?

Enzon Pharmaceuticals, Inc. is a biotechnology company. It discovers, develops, and commercializes therapeutics to treat life-threatening diseases. The Company's marketed drug products include PegIntron (R) for chronic hepatitis C; Sylatron (R) for Melanoma; Macugen (R) for neovascular age-related macular degeneration; CIMZIA (R) for Crohn's disease; Oncaspar for acute lymphoblastic leukemia; and Adagen for severe combined immunedeficiency. Enzon Pharmaceuticals, Inc. is headquartered in Piscataway, New Jersey.


What is the stock price of Enzon Pharmaceuticals today?

The current stock price of ENZN is 0.46 null. The price increased by 2.22% in the last trading session.


Does Enzon Pharmaceuticals pay dividends?

Enzon Pharmaceuticals (ENZN) has a dividend yield of 38.46%. The yearly dividend amount is currently 0.15.


What is the ChartMill rating of Enzon Pharmaceuticals stock?

ENZN has a ChartMill Technical rating of 0 out of 10.You can find more details on the Technical Analysis and Fundamental Analysis tabs.


What is Enzon Pharmaceuticals worth?

Enzon Pharmaceuticals (ENZN) has a market capitalization of 20.34M null. This makes ENZN a Nano Cap stock.